Novavax: applies to FDA for Covid 2024/25 vaccine
(CercleFinance.com) - Novavax announced that it had applied for Emergency Use Authorization in the US for its COVID-19 vaccine formula 2024-2025 (NVX-CoV2705) in June.
The FDA is committed to reviewing the application promptly, and Novavax expects to obtain approval in time for the peak vaccination season.
The vaccine, targeting the JN.1 strain and its variants, will be available in pre-filled syringes at thousands of outlets nationwide.
Once licensed, it will be the only protein-based vaccine available in the US for people aged 12 and over.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The FDA is committed to reviewing the application promptly, and Novavax expects to obtain approval in time for the peak vaccination season.
The vaccine, targeting the JN.1 strain and its variants, will be available in pre-filled syringes at thousands of outlets nationwide.
Once licensed, it will be the only protein-based vaccine available in the US for people aged 12 and over.
Copyright (c) 2024 CercleFinance.com. All rights reserved.